keyword
MENU ▼
Read by QxMD icon Read
search

tocilizumab

keyword
https://www.readbyqxmd.com/read/28094756/treatment-modifying-factors-of-biologics-for-psoriatic-arthritis-a-systematic-review-and-bayesian-meta-regression
#1
REVIEW
Eric Druyts, Jacqueline B Palmer, Chakrapani Balijepalli, Keith Chan, Mir Sohail Fazeli, Vivian Herrera, Jeroen P Jansen, Jay J H Park, Steve Kanters, Andreas Reimold
OBJECTIVES: The aim of this study was to explore factors that modify treatment effects of non-conventional biologics versus placebo in patients with psoriatic arthritis. METHODS: A systematic literature review and meta-regression was conducted. The biologics included etanercept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab, tocilizumab, anakinra, abatacept, rituximab, and secukinumab. Outcomes included American College of Rheumatology (ACR) 20 and 50, Psoriasis Area Severity Index (PASI) 75, and 36-Item Short Form Health Survey (SF-36) Physical and Mental Component Summaries (PCS and MCS)...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28094589/leucine-rich-%C3%AE-2-glycoprotein-as-the-acute-phase-reactant-to-detect-systemic-juvenile-idiopathic-arthritis-disease-activity-during-anti-interleukin-6-blockade-therapy-a-case-series
#2
Masaki Shimizu, Yasuo Nakagishi, Natsumi Inoue, Mao Mizuta, Akihiro Yachie
OBJECTIVES: To assess the role of leucine-rich α2-glycoprotein (LRG) as a biomarker for monitoring systemic juvenile idiopathic arthritis (s-JIA) disease activity during interleukin (IL)-6 blockade treatment. METHODS: We serially measured serum LRG levels in four s-JIA patients treated with the anti-IL-6 receptor antibody tocilizumab and determined the correlation between clinical symptoms and other inflammatory biomarkers and proinflammatory cytokines, including IL-18, IL-6, neopterin, and tumor necrosis factor-α receptor type I and II...
January 17, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28079510/a-comparison-of-discontinuation-rates-of-tofacitinib-and-biologic-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-a-systematic-review-and-bayesian-network-meta-analysis
#3
Sun-Kyeong Park, Min-Young Lee, Eun-Jin Jang, Hye-Lin Kim, Dong-Mun Ha, Eui-Kyung Lee
OBJECTIVES: The purpose of this study was to compare the discontinuation rates of tofacitinib and biologics (tumour necrosis factor inhibitors (TNFi), abatacept, rituximab, and tocilizumab) in rheumatoid arthritis (RA) patients considering inadequate responses (IRs) to previous treatment(s). METHODS: Randomised controlled trials of tofacitinib and biologics - reporting at least one total discontinuation, discontinuation due to lack of efficacy (LOE), and discontinuation due to adverse events (AEs) - were identified through systematic review...
January 5, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28079502/subcutaneous-panniculitis-like-t-cell-lymphoma-with-haemophagocytic-syndrome-during-tocilizumab-therapy-for-juvenile-idiopathic-arthritis
#4
Hiroyuki Nakamura, Tatsuro Sugai, Masaru Kato, Kanako C Hatanaka, Tatsuya Atsumi
****************************************************************************.
January 5, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28079265/chimeric-antigen-receptor-t-cells-in-hematologic-malignancies
#5
Brandon R Shank, Bryan Do, Adrienne Sevin, Sheree E Chen, Sattva S Neelapu, Sandra B Horowitz
Patients with B cell hematologic malignancies who progress through first or second line chemotherapy have a poor prognosis. Early clinical trials with autologous anti-CD19 chimeric antigen receptor (CAR) T cells have demonstrated promising results for patients who have relapsed or refractory disease. Lymphodepleting conditioning regimens including cyclophosphamide, fludarabine, pentostatin, bendamustine, interleukin-2, and total body irradiation are often administered prior to infusion of CAR T cells, allowing for greater T cell expansion...
January 12, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28058538/factors-influencing-the-choice-of-first-and-second-line-biologic-therapy-for-the-treatment-of-rheumatoid-arthritis-real-life-data-from-the-italian-lorhen-registry
#6
Sara Monti, Catherine Klersy, Roberto Gorla, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Raffaele Pellerito, Enrico Fusaro, Giuseppe Paolazzi, Pier Andrea Rocchetta, Ennio Giulio Favalli, Antonio Marchesoni, Roberto Caporali
According to international recommendations, the selection of the biologic disease modifying anti-rheumatic drug (bDMARD) for rheumatoid arthritis (RA) is mainly left to the clinician's preference. We analyzed the real-life factors influencing the first-line choice or the switching strategy, focusing on the prescription of abatacept (ABA) or tocilizumab (TCZ) compared to TNFα inhibitors (TNFi). Patients enrolled in the Lombardy Rheumatology Network (LORHEN) Registry after January 1, 2010, when all considered bDMARD agents were available, were included...
January 5, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28053020/blocking-tumor-educated-msc-paracrine-activity-halts-osteosarcoma-progression
#7
Serena Rubina Baglio, Tonny Lagerweij, Maria Pérez Lanzón, Dung Xuan Ho, Nicolas Léveillé, Sonia A Melo, Anne-Marie Cleton-Jansen, Ekaterina S Jordanova, Laura Roncuzzi, Michelina Greco, Monique A J van Eijndhoven, Giulia Grisendi, Massimo Dominici, Roberta Bonafede, Sinead Lougheed, Tanja D de Gruijl, Nicoletta Zini, Silvia Cervo, Agostino Steffan, Vincenzo Canzonieri, Aare Martson, Katre Maasalu, Sulev Koks, Thomas Wurdinger, Nicola Baldini, Dirk M Pegtel
PURPOSE: Human osteosarcoma is a genetically heterogeneous bone malignancy with poor prognosis despite the employment of aggressive chemotherapy regimens. Because druggable driver mutations have not been established, dissecting the interactions between osteosarcoma cells and supporting stroma may provide insights into novel therapeutic targets. EXPERIMENTAL DESIGN: By using a bioluminescent orthotopic xenograft mouse model of osteosarcoma we evaluated the effect of tumor extracellular vesicle (EV)-educated mesenchymal stem cells (TEMSCs) on osteosarcoma progression...
January 4, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28041910/necrotizing-fasciitis-in-a-patient-receiving-tocilizumab-for-rheumatoid-arthritis-case-report
#8
Diana Rosa-Gonçalves, Miguel Bernardes, Lúcia Costa
We present a case of necrotizing fasciitis in a 66-year-old Caucasian woman with rheumatoid arthritis receiving tocilizumab, and provide a review of published cases. The patient exhibited no systemic symptoms and discreet cutaneous inflammatory signals at presentation. She was successfully treated with broad-spectrum empiric antibiotic therapy and surgical debridement.
December 29, 2016: Reumatología Clinica
https://www.readbyqxmd.com/read/28034349/biological-agents-in-rheumatoid-arthritis-a-cross-link-between-immune-tolerance-and-immune-surveillance
#9
Rossella Talotta, Fabiola Atzeni, Alberto Batticciotto, Maurizio Benucci, Sara Bongiovanni, Piercarlo Sarzi-Puttini
The biological drugs have all been successfully used to treat rheumatoid arthritis (RA) and have led to fair rates of clinical remission; however, the possible occurrence of adverse events such as infectious diseases or cancers means that the patients undergoing treatment need to be closely monitored. Anti-TNF agents, first appeared in the pharmacological algorithm of RA in the early 2000s, seem to lead to a higher risk of reactivated tubercular infection than the biological agents with different mechanism of action (abatacept or rituximab)...
December 30, 2016: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/28027930/tocilizumab-improves-the-proatherothrombotic-profile-of-rheumatoid-arthritis-patients-modulating-endothelial-dysfunction-netosis-and-inflammation
#10
P Ruiz-Limón, R Ortega, I Arias de la Rosa, M C Abalos-Aguilera, C Perez Sanchez, Y Jimenez Gomez, E Peralbo-Santaella, P Font, D Ruiz-Vilches, G Ferrin, E Collantes-Estevez, A Escudero, C H López Pedrera, N Barbarroja
Tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). However, the changes that occurred after TCZ therapy on endothelial dysfunction, monocyte activity, NETosis, and oxidative stress, the principal effectors of atherosclerosis and cardiovascular disease, have not been analyzed yet. A total of 20 RA patients received 162 mg per week subcutaneous TCZ for 6 months. Endothelial function was measured through postocclusive hyperemia using Laser Doppler. Oxidative stress markers in monocytes and neutrophils were analyzed by flow cytometry...
December 9, 2016: Translational Research: the Journal of Laboratory and Clinical Medicine
https://www.readbyqxmd.com/read/28018840/hand-impairment-in-systemic-sclerosis-various-manifestations-and-currently-available-treatment
#11
Amber Young, Rajaie Namas, Carole Dodge, Dinesh Khanna
Systemic sclerosis (SSc) is an autoimmune disease initially recognized by hand involvement due to characteristic Raynaud's phenomenon (RP), puffy hands, skin thickening, and contractures resembling claw deformities. SSc contributes to hand impairment through inflammatory arthritis, joint contractures, tendon friction rubs (TFRs), RP, digital ulcers (DU), puffy hands, skin sclerosis, acro-osteolysis, and calcinosis. These manifestations, which often co-exist, can contribute to difficulty with occupational activities and activities of daily living (ADL), which can result in impaired quality of life...
September 2016: Current Treatment Options in Rheumatology
https://www.readbyqxmd.com/read/28013201/risk-of-serious-adverse-effects-of-biological-and-targeted-drugs-in-patients-with-rheumatoid-arthritis-a-systematic-review-meta-analysis
#12
Simon Tarp, Daniel Eric Furst, Maarten Boers, George Luta, Henning Bliddal, Ulrik Tarp, Karsten Heller Asmussen, Birgitte Brock, Anna Dossing, Tanja Schjødt Jørgensen, Steffen Thirstrup, Robin Christensen
OBJECTIVES: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. METHODS: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28013198/effect-of-tocilizumab-on-neutrophils-in-adult-patients-with-rheumatoid-arthritis-pooled-analysis-of-data-from-phase-3-and-4-clinical-trials
#13
Robert J Moots, Anthony Sebba, William Rigby, Andrew Ostor, Benjamin Porter-Brown, Francis Donaldson, Sophie Dimonaco, Andrea Rubbert-Roth, Ronald van Vollenhoven, Mark C Genovese
OBJECTIVES: To investigate changes in neutrophil count and occurrences of infection in RA patients treated with the IL-6 receptor-α inhibitor tocilizumab (TCZ). METHODS: Data were pooled from patients who received i.v. TCZ (4 mg/kg + MTX, 8 mg/kg ± DMARDs, 10 mg/kg) or placebo + DMARDs in phase 3/4 clinical trials, long-term extensions or a pharmacology study. Neutrophil counts were measured routinely according to the Common Toxicity Criteria for Adverse Events grades; TCZ dosing was adjusted if necessary...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28010149/outcomes-of-tumor-necrosis-factor-inhibitor-cycling-versus-switching-to-a-disease-modifying-anti-rheumatic-drug-with-a-new-mechanism-of-action-among-patients-with-rheumatoid-arthritis
#14
Benjamin Chastek, Laura K Becker, Chieh-I Chen, Puneet Mahajan, Jeffrey R Curtis
OBJECTIVES: To examine treatment patterns, treatment effectiveness, and treatment costs for 1 year after patients with rheumatoid arthritis switched from a tumor necrosis factor inhibitor (TNFi) (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), either cycling to another TNFi ("TNFi cyclers") or switching to a new mechanism of action (abatacept, tocilizumab, or tofacitinib) ("new MOA switchers"). METHODS: This retrospective cohort study used administrative claims data for a national insurer...
January 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28007755/low-immunogenicity-of-tocilizumab-in-patients-with-rheumatoid-arthritis
#15
Gerd R Burmester, Ernest Choy, Alan Kivitz, Atsushi Ogata, Min Bao, Akira Nomura, Stuart Lacey, Jinglan Pei, William Reiss, Attila Pethoe-Schramm, Navita L Mallalieu, Thomas Wallace, Margaret Michalska, Herbert Birnboeck, Kay Stubenrauch, Mark C Genovese
OBJECTIVE: Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy and safety observed in clinical trials. Anti-TCZ antibody development and its impact on safety and efficacy were evaluated in adult patients with RA treated with intravenous TCZ (TCZ-IV) or TCZ-SC as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODS: Data from 5 TCZ-SC and 8 TCZ-IV phase III clinical trials and 1 TCZ-IV clinical pharmacology safety study (>50 000 samples) were pooled to assess the immunogenicity profile of TCZ-SC and TCZ-IV (8974 total patients)...
December 22, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27998620/newly-diagnosed-vs-relapsing-giant-cell-arteritis-baseline-data-from-the-giacta-trial
#16
Katie Tuckwell, Neil Collinson, Sophie Dimonaco, Micki Klearman, Daniel Blockmans, Elisabeth Brouwer, Maria C Cid, Bhaskar Dasgupta, Juergen Rech, Carlo Salvarani, Sebastian H Unizony, John H Stone
OBJECTIVE: To report entry criteria and clinical features of patients with newly diagnosed and relapsing giant cell arteritis (GCA) enrolled in a randomized trial of tocilizumab, an interleukin-6 receptor-alpha inhibitor. METHODS: Newly diagnosed GCA was defined as diagnosis ≤6 weeks before baseline. Relapsing GCA was defined as diagnosis >6 weeks before baseline with ≥2 consecutive weeks of prednisone ≥40mg/day. All patients had active GCA within 6 weeks of baseline...
November 15, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27995982/crosstalk-between-activated-microglia-and-neurons-in-the-spinal-dorsal-horn-contributes-to-stress-induced-hyperalgesia
#17
Jian Qi, Chen Chen, Qing-Xi Meng, Yan Wu, Haitao Wu, Ting-Bao Zhao
Stress has been shown to enhance pain sensitivity resulting in stress-induced hyperalgesia. However, the underlying mechanisms have yet to be elucidated. Using single-prolonged stress combined with Complete Freund's Adjuvant injection model, we explored the reciprocal regulatory relationship between neurons and microglia, which is critical for the maintenance of posttraumatic stress disorder (PTSD)-induced hyperalgesia. In our assay, significant mechanical allodynia was observed. Additionally, activated neurons in spinal dorsal horn were observed by analysis of Fos expression...
December 20, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27994990/refractory-case-of-takayasu-arteritis-in-a-young-woman-a-clinical-challenge
#18
Mudassar Ahmed, Salman Mansoor, Salman Assad, Shahar Y Khan, Rizwanullah Khan, Usman Ghani, Taimur Mansoor, Aasim Rehman
Takayasu arteritis (TA) is an idiopathic chronic inflammatory vasculitis of the aorta and its main branches, which if not treated can lead to severe vascular damage and fatal vascular events. Glucocorticoids (GCs) are the mainstay of the therapy of TA but a significant proportion of patients tend to experience flare-ups when their GCs are tapered. We report a case of a 42-year-old female with TA, diagnosed according to the 1990 American College of Rheumatology Criteria for TA. Cardiovascular assessment showed normal carotid upstrokes with bilateral carotid bruits and soft right and left subclavian bruits with weak peripheral pulses...
November 9, 2016: Curēus
https://www.readbyqxmd.com/read/27989499/biological-agents-in-polyarticular-juvenile-idiopathic-arthritis-a-meta-analysis-of-randomized-withdrawal-trials
#19
Gil Amarilyo, Simon Tarp, Ivan Foeldvari, Neta Cohen, Tracy D Pope, Jennifer M P Woo, Robin Christensen, Daniel E Furst
BACKGROUND AND OBJECTIVE: Although various biological agents are in use for polyarticular juvenile idiopathic arthritis (pJIA), head-to-head trials comparing the efficacy and safety among them are lacking. We aimed to compare the efficacy and safety of biological agents in pJIA using all currently available randomized withdrawal trials (wRCTs). METHODS: A systematic search of MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov was performed. Eligible wRCTs: patients with pJIA where a biological agent was compared with another biological agent or placebo...
December 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27984003/a-systematic-analysis-of-treatment-and-outcomes-of-nod2-associated-autoinflammatory-disease
#20
Qingping Yao, Bo Shen
OBJECTIVES: Yao syndrome, formerly named NOD2-associated autoinflammatory disease, is a periodic disease characterized by fever, dermatitis, polyarthritis/leg swelling, and gastrointestinal and sicca-like symptoms associated with specific NOD2 sequence variants. Our aim was to evaluate the treatment and outcomes of the disease. METHODS: A total of 52 adult patients with autoinflammatory disease phenotype were diagnosed with Yao syndrome and enrolled at the Cleveland Clinic between November 2009 and May 2015...
October 28, 2016: American Journal of Medicine
keyword
keyword
5841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"